Actos Franchise Drives Takeda's Pharmaceutical Sales Growth
This article was originally published in The Pink Sheet Daily
Firm continues FDA discussions for new cholesterol candidate Tak-475.
You may also be interested in...
Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.